Skip to main content
. 2021 Nov 24;7(48):eabl6432. doi: 10.1126/sciadv.abl6432

Fig. 5. Anti-osteoporosis efficacy of RAW-PLGA nanodecoys in OVX mice.

Fig. 5.

(A) Time line of the in vivo study. Female C57/BL6 mice were subjected to bilateral ovariectomy. In the next 60 days, PBS, PLGA NPs, or RAW-PLGA nanodecoys were intravenously (i.v.) injected at 10 mg PLGA/kg every 3 days, and mice were sacrificed on day 60 for analysis. Mice without ovariectomy or NP/nanodecoy treatment served as the normal control. RANKL (B) and TNF-α (C) levels in the serum (n = 6). (D) Relative mRNA levels of RANKL/RANK/OPG system genes (RANKL, RANK, and TRAF6), osteoclast-related transcription factors (NFATc1 and c-Fos), osteoclast-specific genes (ctsK, TRAP, and RECK), and bone resorption–related genes (MMP2, MMP9, and MMP13) in the femoral tissues (n = 6). TRACP-5b (E), BGP (F), and BAP (G) levels in the serum (n = 6).